Publication Detail

Citation : Lin C, Grandinetti A, Shikuma C, Souza S, Parikh N, Nakamoto B, Kallianpur KJ, Chow D. (2013)
The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients.
Hawaii J Med Public Health 72(4):123-7.
Abstract : With the advent of highly active antiretroviral therapy (HAART), Cardiovascular Disease (CVD) has emerged as the leading cause of death in Human Immunodeficiency Virus (HIV) infected patients. An atherogenic lipoprotein phenotype has been described in HIV- infected patients with a predominance of small, low density lipoprotein (SLDL) particles with accompanying elevated triglycerides and reduced high density lipoprotein cholesterol. This randomized controlled pilot study was conducted to evaluate the efficacy of Extended Release Niacin (ERN) in improving the lipid profile in HIV patients. A total of 17 HIV positive subjects on HAART therapy with High Density Lipoprotein Cholesterol (HDL) levels below 40mg/dl and Low Density Lipoprotein Cholesterol (LDL) below 130mg/dl were enrolled. Nine were randomized to be treated with ERN titrated from a starting level of 500mg/night and titrated to a level of 1500mg/night. Eight patients were assigned to the control arm. No placebo was used. Lipoprotein profiles of the subjects were analyzed at baseline and at the end of 12 weeks using Nuclear Magnetic Resonance (NMR) spectroscopy. At the end of 12 weeks, NMR spectroscopic analysis revealed a significant increase in overall LDL size (1.2% in ERN treated subjects vs 2.0% decrease in control patients, P=.04) and a decrease in small LDL particle concentration (17.0% in ERN treated subjects vs 21.4% increase in control patients, P=.03) in subjects receiving ERN as compared to those in the control group. Only 1 subject receiving ERN developed serious flushing which was attributed to an accidental overdose of the drug. This pilot study demonstrates that ERN therapy in HIV-infected patients with low HDL is safe and effective in improving the lipoprotein profile in these patients.
URL Link : http://www.ncbi.nlm.nih.gov/pubmed/23795312
PMID : 23795312
PMCID : PMC3689507
News
02 February 2018:
The Mary Kay Foundation - GRANT APPLICATION ANNOUNCEMENT

The Mary Kay Foundation

GRANT APPLICATION ANNOUNCEMENT

Applications are accepted from
November 2, 2017 through February 2, 2018

DEADLINE is …

08 December 2017:
F31 Award Submission Alert

The Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (F31 …

06 November 2017:
NRMN Grant Writing Coaching Group Applications

Are you preparing a proposal to submit to NIH in the upcoming months? Do you want to be coached on effective writing techniques from experienced grant…


View more news...


Seminars & Events
16 June 2017, 9am - 10:30am:
HEALTH & MEDICINE SEMINAR - Kukulu Ola Hou
02 June 2017, 8:15am - 4:10pm:
PROMOTING EXCELLENCE IN CLINICAL RESEARCH
02 November 2016, 9am:
RMATRIX-II Collaboration Pilot Projects Program 2017 -- Informational Webinar

View more seminars & events...

Supported by a grant from the National Institute on Minority Health and Health Disparities (U54MD007584), National Institutes of Health.